- CTC Detection
- CTC Enrichment
- CTC Analysis
Circulating Tumor Cell (CTC) Testing Market size was valued at USD 9.4 billion in 2022 and is poised to grow at a CAGR of 11.7% from 2023-2029. Circulating Tumor Cell (CTC) Testing is a simple blood test that helps oncologists to assess the prognosis of patients with metastatic colorectal, breast, or prostate cancer. The cell search test is the only FDA-approved test for CTC assessment. CTC are the cancer cells that detach from solid tumors and enter the bloodstream. The global market is highly fragmented with small biotech firms holding a chunk of the overall industry share. CTC is very rare that on average only 1 CTC is present in 1 billion blood cells and CTC clusters are even rarer. The recent development of cluster chips has been successful in capturing CTC clusters ranging between 2-17 cells is an important development in the global market. According to WHO, cancer incidence is projected to rise by 50% to reach 15 million by the end of this decade. This alarming increase in the number of patients necessitates this as a potential treatment approach addressing the growing global burden of the disease. Biotech firms dominate the global circulating tumor cell (CTC) testing market. The players are constantly engaged in R&D in order to develop novel methods to treat cancers. Favorable government initiatives will fuel global circulating tumor cell (CTC) testing market size. For instance, CDC supports nationwide screening programs for control of breast, cervical, and colorectal cancer among low-income women with little or no health insurance.
Circulating Tumor Cell Ctc Testing Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
11.7%
Largest Market
Europe
Fastest Growing Market
North-America
Circulating Tumor Cell (CTC) Testing Market Dynamics
Increasing in number of cancer cases and rise in geriatric population are the major factors which are attributing for the growth of the circulating tumor cell (CTC) testing market globally. As per the WHO statistics cancer accounts for 13% of deaths globally every year, moreover 70% increase in cancer incidences is anticipated over the next couple of decades and global geriatric population is anticipated to nearly double from 12% to 22% from 2015 to 2022. Furthermore, advanced technologies in circulating tumor cell (CTC) testing, improved healthcare expenditure, growing awareness regarding circulating tumor cell (CTC) testing and increased government support are the few more factors which are boosting the growth of circulating tumor cell (CTC) testing market globally. However, stringent regulatory framework, prolonged time of approvals for product launching and cost containment measures are the few factors restraining the growth of circulating tumor cell (CTC) testing market globally.
North-America Got Significant Share
Circulating Tumor Cell (CTC) Testing Market Regional Analysis
Geographically, global market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America dominates the global market for due to a large number of aging population and technological advancement in the region, heavy investments in R & D activities along with government support will boost the industry demand over the coming years. The UK market is anticipated to grow rapidly over the forecast timeline due to the rising occurrence of cancer along with increasing acceptance of advanced technology. Asia is expected to witness high growth in circulating tumor cell (CTC) testing market, due to increasing government initiatives, rising economy, and improvement in healthcare infrastructure in the region. Some of the key driving forces for circulating tumor cell (CTC) testing market in emerging countries are increasing R&D investment, a large pool of patients and rising government funding.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup’s details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Circulating Tumor Cell Ctc Testing Market Segmentation
By Technology
By Application
- EMT biomarkers development
- Cancer stem cell research
- Tumorigenesis research
- Others
By End-User
- Diagnostic Centers
- Hospitals
- Ambulatory Surgical Centers
Frequently Asked Questions
The circulating tumor cell (CTC) testing market is projected to expand at a CAGR of 11.7% during the forecast period
Fluxion Biosciences, Clearbridge BioMedics, Adnagen, Apocell, Advanced Cell Diagnostics, Cynvenio Biosystems
North America is the fastest-growing region for the circulating tumor cell (CTC) testing market
| 1. Executive Summary |
| 2. Global Circulating Tumor Cell (CTC) Testing Market Introduction |
| 2.1.Global Circulating Tumor Cell (CTC) Testing Market - Taxonomy |
| 2.2.Global Circulating Tumor Cell (CTC) Testing Market - Definitions |
| 2.2.1.Technology |
| 2.2.2.Application |
| 2.2.3.End User |
| 2.2.4.Region |
| 3. Global Circulating Tumor Cell (CTC) Testing Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4. Global Circulating Tumor Cell (CTC) Testing Market Analysis, 2018 - 2022 and Forecast 2023 - 2029 |
| 4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Circulating Tumor Cell (CTC) Testing Market By Technology, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 5.1. CTC Detection |
| 5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. CTC Enrichment |
| 5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. CTC Analysis |
| 5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 6. Global Circulating Tumor Cell (CTC) Testing Market By Application, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 6.1. EMT biomarkers development |
| 6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Cancer stem cell research |
| 6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Tumorigenesis research |
| 6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Others |
| 6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 7. Global Circulating Tumor Cell (CTC) Testing Market By End User, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 7.1. Diagnostic Centers |
| 7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Hospitals |
| 7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Ambulatory Surgical Centers |
| 7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8. Global Circulating Tumor Cell (CTC) Testing Market By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9. North America Circulating Tumor Cell (CTC) Testing Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 9.1. Technology Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.CTC Detection |
| 9.1.2.CTC Enrichment |
| 9.1.3.CTC Analysis |
| 9.2. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.EMT biomarkers development |
| 9.2.2.Cancer stem cell research |
| 9.2.3.Tumorigenesis research |
| 9.2.4.Others |
| 9.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Diagnostic Centers |
| 9.3.2.Hospitals |
| 9.3.3.Ambulatory Surgical Centers |
| 9.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10. Europe Circulating Tumor Cell (CTC) Testing Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 10.1. Technology Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.CTC Detection |
| 10.1.2.CTC Enrichment |
| 10.1.3.CTC Analysis |
| 10.2. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.EMT biomarkers development |
| 10.2.2.Cancer stem cell research |
| 10.2.3.Tumorigenesis research |
| 10.2.4.Others |
| 10.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Diagnostic Centers |
| 10.3.2.Hospitals |
| 10.3.3.Ambulatory Surgical Centers |
| 10.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 10.4.6.Rest of EU |
| 11. Asia Pacific (APAC) Circulating Tumor Cell (CTC) Testing Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 11.1. Technology Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.CTC Detection |
| 11.1.2.CTC Enrichment |
| 11.1.3.CTC Analysis |
| 11.2. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.EMT biomarkers development |
| 11.2.2.Cancer stem cell research |
| 11.2.3.Tumorigenesis research |
| 11.2.4.Others |
| 11.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Diagnostic Centers |
| 11.3.2.Hospitals |
| 11.3.3.Ambulatory Surgical Centers |
| 11.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12. Middle East and Africa (MEA) Circulating Tumor Cell (CTC) Testing Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 12.1. Technology Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.CTC Detection |
| 12.1.2.CTC Enrichment |
| 12.1.3.CTC Analysis |
| 12.2. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.EMT biomarkers development |
| 12.2.2.Cancer stem cell research |
| 12.2.3.Tumorigenesis research |
| 12.2.4.Others |
| 12.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Diagnostic Centers |
| 12.3.2.Hospitals |
| 12.3.3.Ambulatory Surgical Centers |
| 12.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13. Latin America Circulating Tumor Cell (CTC) Testing Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 13.1. Technology Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.CTC Detection |
| 13.1.2.CTC Enrichment |
| 13.1.3.CTC Analysis |
| 13.2. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.EMT biomarkers development |
| 13.2.2.Cancer stem cell research |
| 13.2.3.Tumorigenesis research |
| 13.2.4.Others |
| 13.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Diagnostic Centers |
| 13.3.2.Hospitals |
| 13.3.3.Ambulatory Surgical Centers |
| 13.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.Fluxion Biosciences (U.S.), |
| 14.2.2.Clearbridge BioMedics (Singapore) |
| 14.2.3.Adnagen (Germany), Apocell (U.S.) |
| 14.2.4.Advanced Cell Diagnostics (U.S.) |
| 14.2.5.Cynvenio Biosystems (U.S.) |
| 14.2.6.Aviva Biosciences (U.S.) |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
- Fluxion Biosciences (U.S.),
- Clearbridge BioMedics (Singapore)
- Adnagen (Germany), Apocell (U.S.)
- Advanced Cell Diagnostics (U.S.)
- Cynvenio Biosystems (U.S.)
- Aviva Biosciences (U.S.)
- Biocept Inc. (U.S.)
- Canopus Biosciences (U.S.)
- Biofluidica (U.S.)